The 300-patient study is designed for optimizing Cellsway’s CTC enrichment, identification and characterization workflow with clinical samples. The patients for the study are being selected from newly diagnosed Stage III/IV breast, non-small-cell lung, and colorectal cancer patients. The study is one of the largest of its kind and four hospitals are involved in the study namely Liv Hospital, Ankara City Hospital, Hacettepe University Hospital, and Gülhane Training and Research Hospital.
The patient recruitment in the frame of the study started in late 2022. To date, we have obtained approximately 150 blood samples from participants, contributing to substantial progress in both sample processing and refinement of our assay protocols. The study is planned to be finalized by the end of 2024.
The principal investigators involved in the clinical study, concurrently serving as Advisory Board Members of Cellsway, have conveyed their keen interest in the study and the prospective advantages of Cellsway’s workflow for both patients and clinicians in the following manner:
Study Coordinator-Prof. Dr. Saadettin Kılıçkap (Medical Oncology, Liv Ankara Hospital) – “Liquid biopsy is a technology that is rapidly spreading all over the world and that we follow closely. We believe that Cellsway’s advanced CTC liquid biopsy technology will stand out in international competition and provide significant benefits for the follow-up and treatment of cancer patients.”
Prof. Dr. Mehmet Ali Şendur (Medical Oncology, Ankara City Hospital) – “We are very excited about this clinical study. We think that molecular analyses on CTCs captured by Cellsway’s system will help clinicians in planning a personalized treatment and increase the success of treatment.”
Prof. Dr. Nuri Karadurmuş (Medical Oncology, Gülhane Hospital) – “Cellsway’s liquid biopsy system results in highly reliable and efficient CTC isolation. Analysis of the CTCs at the downstream will provide valuable clinical information for real-time disease monitoring and therapy guidance.”